The burgeoning field of metabolic disease management is witnessing a remarkable convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://asiyaqzix848368.link4blogs.com/62653648/both-medications-and-nad-a-triple-threat-system-to-metabolic-condition